Twitxy
Saved
@exosome's profile picture
View on X

Dr. Thomas Ichim

Verified account This account is verified. Learn more

@exosome

President and Chief Scientific Officer of @Immortabio
immortabio.com
505 patents
132 pubmed papers pubmed.ncbi.nlm.nih.gov/?term=ichim+t
La Jolla, CA immortabio.com Joined December 2012
41K Following 43K Followers 69K Posts

Latest posts 5

Pinned post

Dr. Thomas Ichim Verified account @exosome
The first use of a senolytic immunotherapy in people!

Thankful for my team @immortabio

SenoMune-0257

prnewswire.com/news-releases/…
www.prnewswire.com First Human Administration of Senolytic Immunotherapy to Fight Cellular Aging Announced by Immorta... /PRNewswire/ -- Immorta Bio, Inc. today announced the first human administration of SenoMune™-0257, an investigational immunotherapy designed to help the...
16 replies 11 reposts 131 likes 76K views View on X
Dr. Thomas Ichim Verified account @exosome
Solid tumors escape CAR-T cells by expressing different antigens. Researchers engineered glioblastoma CAR-T cells to secrete an EGFR-targeting T-cell engager. In three patients, tumors regressed within days, although responses were transient in two.

doi.org/10.1056/NEJMoa…
www.nejm.org Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma | NEJM In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T ...
Dr. Thomas Ichim Verified account @exosome
CAR-T cells delivered through the bloodstream may not adequately reach brain tumors. In one glioblastoma patient, intraventricular IL13Rα2 CAR-T administration produced regression of all detectable brain and spinal tumors. The response lasted 7.5 months before recurrence.

doi.org/10.1056/NEJMoa…
www.nejm.org Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | NEJM A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multip...
Dr. Thomas Ichim Verified account @exosome
In a glioblastoma trial, CAR-T cells entered tumors, but surviving cancer cells showed reduced EGFRvIII antigen expression and increased immunosuppressive signals. Targeting multiple antigens may reduce this mechanism of tumor escape.

doi.org/10.1126/scitra…
www.science.org A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and... A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.